Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - BIOTECH HOLDRS TRUST | ss128134_8k-biotech.htm |
|
PROSPECTUS SUPPLEMENT
|
EXHIBIT 99.1
|
|
(To Prospectus dated March 15, 2011)
|
REGISTRATION NO. 333-89355
|
1,000,000,000 Depositary Receipts
Biotech HOLDRS (SM) Trust
This prospectus supplement supplements information contained in the prospectus dated March 15, 2011 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust.
The share amounts specified in the table in the “Highlights of Biotech HOLDRS” section of the base prospectus shall be replaced with the following:
|
Name of Company
|
Ticker
|
Share Amounts
|
Primary U.S.
Trading Market |
|||
|
Affymetrix, Inc.
|
AFFX
|
4.0000 |
NASDAQ GS
|
|||
|
Alkermes plc1
|
ALKS
|
4.0000 |
NASDAQ GS
|
|||
|
Amgen Inc.
|
AMGN
|
64.4800 |
NASDAQ GS
|
|||
|
Biogen Idec Inc.
|
BIIB
|
26.9500 |
NASDAQ GS
|
|||
|
Enzon Pharmaceuticals, Inc.
|
ENZN
|
3.0000 |
NASDAQ GM
|
|||
|
Gilead Sciences, Inc.
|
GILD
|
64.0000 |
NASDAQ GS
|
|||
|
Human Genome Sciences, Inc.
|
HGSI
|
8.0000 |
NASDAQ GM
|
|||
|
Life Technologies Corporation
|
LIFE
|
8.1774 |
NASDAQ GS
|
|||
|
QLT Inc.
|
QLTI
|
5.0000 |
NASDAQ GS
|
|||
|
Shire plc
|
SHPGY
|
6.8271 |
NASDAQ GS
|
The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.
The date of this prospectus supplement is September 26, 2011.
1 On September 16, 2011, the merger of Alkermes, Inc. and Elan Drug Technologies to form Alkermes plc became effective. As a result, Alkermes, Inc. will be replaced by Alkermes plc as an underlying constituent of the Biotech HOLDRS Trust. In connection with the merger, Alkermes, Inc. shareholders will receive 1 share of Alkermes plc for each share of Alkermes, Inc. The Bank of New York Mellon will receive 4 shares of Alkermes plc for the 4 shares of Alkermes, Inc. per 100 share round-lot of
Biotech HOLDRS. As a result, creations and cancellations of Biotech HOLDRS will require a deposit of 4 shares of Alkermes plc per 100 share round-lot of Biotech.